GO:0005945 6-phosphofructokinase complex: Components, Assembly and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0005945 defines the 6-phosphofructokinase complex, a protein assembly with 6-phosphofructokinase activity that catalyzes the committed step of glycolysis.
• The complex exists as homodimers, homotetramers, and homooctamers, and its activity is allosterically regulated by ATP and fructose-6-phosphate.
• PFKP, PFKM, and PFKL are the human genes encoding tissue-specific isoforms that form the 6-phosphofructokinase complex.
• Dysregulation of the complex contributes to renal fibrosis, sepsis, cardiovascular disease, and cancer metabolism.
• Post-translational modifications and allosteric effectors modulate complex activity, linking it to phosphorylation-dephosphorylation cascades.
• CRISPR knockout, point mutation, knock-in, and overexpression models enable precise interrogation of 6-phosphofructokinase complex function in disease.
Description
The 6-phosphofructokinase complex (GO:0005945) is a cellular component defined as a protein complex that possesses 6-phosphofructokinase activity, with homodimeric, homooctameric, and allosteric homotetrameric forms known. This complex catalyzes the phosphorylation of fructose-6-phosphate to fructose-1,6-bisphosphate, the committed and rate-limiting step of glycolysis. Because glycolysis is central to energy production and biosynthetic precursor supply, the 6-phosphofructokinase complex is a focal point for metabolic regulation in health and disease. Researchers study this complex to understand how cells adapt metabolism under stress, how allosteric control is achieved at the molecular level, and how its dysfunction contributes to pathologies such as fibrosis, sepsis, and cancer. The complex is also a target for therapeutic strategies aimed at modulating glycolytic flux.
6-phosphofructokinase complex At A Glance
| GO ID | GO:0005945 |
|---|---|
| GO term | 6-phosphofructokinase complex |
| Ontology | cellular_component |
| Synonym | None |
| Major function | Catalyzes the phosphorylation of fructose-6-phosphate to fructose-1,6-bisphosphate, the committed step of glycolysis |
| Subunit composition | Homodimeric, homooctameric, and allosteric homotetrameric forms |
| Allosteric regulation | Inhibited by Mg-ATP2- and shows cooperativity toward fructose-6-phosphate |
| Human genes | PFKP, PFKM, PFKL encode tissue-specific isoforms |
| Associated diseases | Renal fibrosis, sepsis, cardiovascular disease, cancer |
What Is GO:0005945?
The 6-phosphofructokinase complex is a protein assembly that exhibits 6-phosphofructokinase activity, the enzyme activity responsible for converting fructose-6-phosphate to fructose-1,6-bisphosphate. According to the QuickGO definition, the complex can exist as a homodimer, a homooctamer, or an allosteric homotetramer. This structural flexibility underlies its kinetic properties, including cooperativity toward fructose-6-phosphate and inhibition by Mg-ATP2-. The complex is a key node in glycolytic regulation and is conserved from bacteria to humans.
Why Is 6-phosphofructokinase complex Important in Cell Biology?
The 6-phosphofructokinase complex is critically important because it governs the rate-limiting step of glycolysis, a pathway that sustains ATP production and biosynthetic intermediates in proliferating and stressed cells. Its allosteric regulation by ATP and fructose-6-phosphate allows fine-tuned metabolic control, and its dysfunction is implicated in diverse pathologies including renal fibrosis, sepsis, cardiovascular disease, and cancer. Understanding the complex at structural and regulatory levels provides opportunities for therapeutic intervention.
• Catalyzes the committed step of glycolysis, controlling carbon flux into energy production and biosynthesis.
• Allosteric regulation by ATP and fructose-6-phosphate integrates cellular energy status.
• Tissue-specific isoforms PFKP, PFKM, and PFKL allow metabolic specialization.
• Inhibition of PFKP restrains TGF-beta-induced glycolysis and renal fibrosis.
• Targeting PFKM with nanobody Nb07 mitigates sepsis by blocking the PFKM-p53-PD-1 axis.
• The complex is a potential therapeutic target in cardiovascular disease.
• PFKFB2 regulates glycolysis and tumor metabolism, impacting cancer therapy.
• Phosphorylation-dephosphorylation cascades modulate enzyme activity, linking signaling to metabolism.
• The complex is conserved in bacteria, enabling structural and kinetic studies.
• Platelet 6-phosphofructokinase is regulated by Mg-ATP2- and shows cooperativity, relevant to thrombosis.
What Happens During 6-phosphofructokinase complex?
Substrate Binding and Catalysis
In simple terms: The complex grabs fructose-6-phosphate and adds a phosphate group to it.
The 6-phosphofructokinase complex binds fructose-6-phosphate and catalyzes its phosphorylation to fructose-1,6-bisphosphate using ATP as the phosphate donor. This reaction is the committed step of glycolysis, meaning once it occurs, the substrate is destined for glycolytic breakdown. Kinetic studies of the Escherichia coli phosphofructokinase-2 complex with fructose-6-phosphate revealed structural details of substrate binding and allosteric ATP inhibition.
Allosteric Regulation by ATP
In simple terms: ATP can bind to a regulatory site and turn the complex off when energy is plentiful.
The complex is allosterically inhibited by Mg-ATP2-, which binds to a regulatory site distinct from the catalytic site. This inhibition is cooperative and modulates the enzyme's affinity for fructose-6-phosphate, allowing the complex to sense cellular energy charge. The crystal structure of the E. coli phosphofructokinase-2 complex with fructose-6-phosphate provided insights into the allosteric ATP inhibition mechanism.
Cooperativity and Ternary Complex Formation
In simple terms: The complex can form a temporary three-part assembly that affects how it responds to substrates.
Human platelet 6-phosphofructokinase exhibits cooperativity toward fructose-6-phosphate, and studies have investigated the formation of a ternary complex involving the enzyme, fructose-6-phosphate, and Mg-ATP2-. This cooperativity ensures a switch-like response to changes in substrate concentration, which is critical for metabolic regulation.
Phosphorylation-Dephosphorylation Control
In simple terms: Adding or removing phosphate groups on the complex can change its activity.
Phosphorylation and dephosphorylation of enzymes, including those in glycolytic pathways, represent a major regulatory mechanism. While specific phosphorylation sites on the 6-phosphofructokinase complex are not detailed in the provided citations, the general principle that reversible phosphorylation modulates enzyme activity is well established.
Key Genes Involved in GO:0005945 6-phosphofructokinase complex
The following genes encode subunits or regulatory proteins associated with the 6-phosphofructokinase complex and its metabolic network.
| Gene | Major Role | Research Relevance |
|---|---|---|
| PFKP | Platelet-type 6-phosphofructokinase; forms the 6-phosphofructokinase complex | Inhibition restrains TGF-beta-induced glycolysis and renal fibrosis |
| PFKM | Muscle-type 6-phosphofructokinase; forms the 6-phosphofructokinase complex | Targeted by nanobody Nb07 to mitigate sepsis via PFKM-p53-PD-1 axis |
| PFKL | Liver-type 6-phosphofructokinase; forms the 6-phosphofructokinase complex | Tissue-specific isoform studied in metabolic regulation |
| PFKFB2 | Regulates fructose-2,6-bisphosphate levels, affecting 6-phosphofructokinase complex activity | Implicated in glycolysis regulation and tumor metabolism |
| PFKFB1 | Regulates fructose-2,6-bisphosphate levels | Potential role in metabolic regulation |
| PFKFB3 | Regulates fructose-2,6-bisphosphate levels | Studied in cancer metabolism |
| PFKFB4 | Regulates fructose-2,6-bisphosphate levels | Studied in cancer metabolism |
| TP53 | Tumor suppressor; interacts with PFKM in sepsis | PFKM-p53-PD-1 axis in macrophage phagocytosis |
| PD-1 | Immune checkpoint; downstream of PFKM-p53 axis | Modulated by PFKM in sepsis |
| TGF-beta | Cytokine driving fibrosis; induces glycolysis via PFKP | Targeted in renal fibrosis studies |
| HIF-1alpha | Transcription factor regulating glycolytic genes | Linked to PFKFB2 and tumor metabolism |
| mTOR | Kinase regulating cell growth and glycolysis | Potential upstream regulator of glycolytic flux |
| AMPK | Energy sensor regulating metabolism | Potential regulator of glycolysis |
| PKM | Pyruvate kinase, downstream glycolytic enzyme | Studied in cardiovascular disease and cancer |
| LDHA | Lactate dehydrogenase, downstream of glycolysis | Studied in cardiovascular disease and cancer |
| HK2 | Hexokinase 2, upstream glycolytic enzyme | Studied in cardiovascular disease and cancer |
| GLUT1 | Glucose transporter | Studied in cardiovascular disease and cancer |
| SLC2A1 | Gene encoding GLUT1 | Studied in cardiovascular disease and cancer |
How Is 6-phosphofructokinase complex Regulated?
The 6-phosphofructokinase complex is regulated by allosteric effectors such as ATP and fructose-6-phosphate, which modulate its activity in response to cellular energy status. Additionally, reversible phosphorylation-dephosphorylation cascades can influence enzyme activity. Upstream signaling pathways, including those involving PFKFB2, regulate the availability of fructose-2,6-bisphosphate, a potent activator of the complex. In disease contexts, TGF-beta signaling induces PFKP expression and glycolysis, contributing to renal fibrosis, while the PFKM-p53-PD-1 axis modulates macrophage phagocytosis in sepsis. These regulatory layers integrate metabolic and immune signals.
6-phosphofructokinase complex and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| PFKP | Renal fibrosis | Knockout or knockdown in renal tubular epithelial cells |
| PFKM | Sepsis | Nanobody treatment or knockout in macrophages |
| PFKFB2 | Cancer | Overexpression or knockout in cancer cell lines |
| PFKL | Cardiovascular disease | Knockout in cardiomyocytes |
| PFKP | Cancer metabolism | Point mutation to alter allosteric regulation |
Renal Fibrosis
Inhibition of PFKP in renal tubular epithelial cells restrains TGF-beta-induced glycolysis and renal fibrosis, suggesting that the 6-phosphofructokinase complex is a driver of fibrotic remodeling. Targeting PFKP may offer a therapeutic strategy for chronic kidney disease.
Sepsis
Nanobody Nb07 mitigates sepsis by blocking the PFKM-p53-PD-1 axis to enhance macrophage phagocytosis, linking the 6-phosphofructokinase complex to immune dysfunction in sepsis. This highlights PFKM as a potential therapeutic target in inflammatory conditions.
Cardiovascular Disease
Glycolytic metabolic pathways, including those involving the 6-phosphofructokinase complex, play a role in cardiovascular disease and are being explored as therapeutic targets. Modulating glycolysis may impact cardiac hypertrophy and heart failure.
Cancer
PFKFB2 regulates glycolysis and tumor metabolism, with implications for cancer therapy. The 6-phosphofructokinase complex is a downstream effector of PFKFB2, making it a key node in cancer metabolic reprogramming.
From 6-phosphofructokinase complex-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does loss of PFKP reduce renal fibrosis? | PFKP knockout in renal tubular epithelial cells |
| Can blocking PFKM improve sepsis outcomes? | PFKM knockout or nanobody Nb07 treatment in macrophages |
| How does allosteric ATP inhibition affect complex activity? | Point mutations in allosteric sites of PFK |
| What is the role of PFKFB2 in tumor metabolism? | PFKFB2 overexpression or knockout in cancer cells |
| Does PFKL contribute to cardiovascular disease? | PFKL knockout in cardiomyocytes |
| How does phosphorylation regulate the complex? | Knock-in of phospho-mimetic or phospho-deficient mutants |
How to Study the 6-phosphofructokinase complex Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Enzyme kinetics | Catalytic activity and allosteric regulation | Assessing PFK complex function |
| X-ray crystallography | Three-dimensional structure | Determining subunit arrangement and ligand binding |
| Metabolic flux analysis | Glycolytic flux | Quantifying pathway activity in cells |
| CRISPR screening | Gene function on a genome-wide scale | Identifying regulators of glycolysis |
| Western blot | Protein expression levels | Validating knockout or overexpression |
| qPCR | mRNA expression levels | Measuring gene expression changes |
| Immunoprecipitation | Protein-protein interactions | Studying complex composition |
Enzyme Kinetics and Allostery
Enzyme kinetics assays measure the catalytic activity of the 6-phosphofructokinase complex and its response to allosteric effectors such as ATP and fructose-6-phosphate. These methods are used to determine kinetic parameters and cooperativity.
Structural Biology
X-ray crystallography and cryo-EM can resolve the structure of the 6-phosphofructokinase complex, revealing subunit arrangement and ligand binding sites. The crystal complex of E. coli phosphofructokinase-2 with fructose-6-phosphate provided structural insights into allosteric ATP inhibition.
Metabolic Flux Analysis
Metabolic flux analysis using isotope tracers measures glycolytic flux through the 6-phosphofructokinase complex step, providing a functional readout of complex activity in cells.
CRISPR Screening
CRISPR library screening can identify genes that modulate 6-phosphofructokinase complex activity or glycolytic flux, enabling unbiased discovery of regulators.
How CRISPR Can Be Used to Study GO:0005945 6-phosphofructokinase complex
Knockout
CRISPR knockout of PFKP, PFKM, or PFKL can abolish 6-phosphofructokinase complex activity, enabling studies of its role in glycolysis and disease. For example, PFKP knockout restrains TGF-beta-induced glycolysis and renal fibrosis, and PFKM knockout can be used to study sepsis mechanisms.
Point Mutation
Point mutations can be introduced into the active site or allosteric sites of the 6-phosphofructokinase complex to dissect catalytic and regulatory mechanisms. Such mutations can mimic or prevent phosphorylation, altering enzyme activity.
Knock-in
Knock-in of tagged or mutant versions of PFK genes allows tracking of complex localization and dynamics. For instance, knock-in of a fluorescent tag can enable live-cell imaging of the complex.
Overexpression
Overexpression of PFKP, PFKM, or PFKL can drive increased glycolytic flux and model disease states such as cancer or fibrosis. This approach is useful for gain-of-function studies.
How EDITGENE Supports 6-phosphofructokinase complex Research
Researchers studying 6-phosphofructokinase complex-related genes often need to determine whether a candidate gene is causally involved in metabolic regulation or disease. EDITGENE provides comprehensive CRISPR-based services to generate precise cell models for such investigations.
Contact EDITGENE today to design your custom CRISPR model for 6-phosphofructokinase complex research.
Frequently Asked Questions About 6-phosphofructokinase complex
What is the 6-phosphofructokinase complex?
The 6-phosphofructokinase complex (GO:0005945) is a protein complex with 6-phosphofructokinase activity that catalyzes the committed step of glycolysis, existing as homodimers, homotetramers, or homooctamers.
What genes are involved in the 6-phosphofructokinase complex?
The human genes PFKP, PFKM, and PFKL encode tissue-specific isoforms that form the complex.
What is the function of the 6-phosphofructokinase complex?
It phosphorylates fructose-6-phosphate to fructose-1,6-bisphosphate, the rate-limiting step of glycolysis.
How is the 6-phosphofructokinase complex regulated?
It is allosterically inhibited by ATP and shows cooperativity toward fructose-6-phosphate, and is also regulated by phosphorylation-dephosphorylation.
What diseases are associated with the 6-phosphofructokinase complex?
It is implicated in renal fibrosis, sepsis, cardiovascular disease, and cancer.
What is the structure of the 6-phosphofructokinase complex?
It can form homodimers, homotetramers, and homooctamers, with allosteric regulation by ATP.
How can I study the 6-phosphofructokinase complex using CRISPR?
CRISPR knockout, point mutation, knock-in, and overexpression models allow functional dissection of the complex in disease contexts.
What is the role of PFKP in renal fibrosis?
Inhibition of PFKP restrains TGF-beta-induced glycolysis and renal fibrosis.
What is the PFKM-p53-PD-1 axis in sepsis?
PFKM interacts with p53 and PD-1 to modulate macrophage phagocytosis, and blocking this axis with nanobody Nb07 mitigates sepsis.
How does PFKFB2 regulate glycolysis?
PFKFB2 regulates fructose-2,6-bisphosphate levels, which activate the 6-phosphofructokinase complex, impacting tumor metabolism.
Conclusion
The 6-phosphofructokinase complex (GO:0005945) is a central metabolic enzyme assembly that catalyzes the committed step of glycolysis and is tightly regulated by allosteric effectors and post-translational modifications. Its dysfunction is linked to renal fibrosis, sepsis, cardiovascular disease, and cancer, making it a compelling therapeutic target. Advances in CRISPR-based models and metabolic profiling continue to unravel its roles in health and disease, offering new avenues for intervention.
References
- 1. Yang S et al.. 2023. Inhibition of PFKP in renal tubular epithelial cell restrains TGF-β induced glycolysis and renal fibrosis.. Cell Death Dis 14(12):816 PMID: 38086793
- 2. Ji B et al.. 2026. Nanobody Nb07 mitigates sepsis by blocking the PFKM-p53-PD-1 axis to enhance macrophage phagocytosis.. Theranostics 16(7):3408-3425 PMID: 41608568
- 4. Krebs EG et al.. 1979. Phosphorylation-dephosphorylation of enzymes.. Annu Rev Biochem 48:923-59 PMID: 38740
- 5. Cabrera R et al.. 2011. The crystal complex of phosphofructokinase-2 of Escherichia coli with fructose-6-phosphate: kinetic and structural analysis of the allosteric ATP inhibition.. J Biol Chem 286(7):5774-83 PMID: 21147773
- 6. Chen S et al.. 2023. The role of glycolytic metabolic pathways in cardiovascular disease and potential therapeutic approaches.. Basic Res Cardiol 118(1):48 PMID: 37938421
- 7. Lou Q et al.. 2025. Regulatory mechanisms of PFKFB2 in glycolysis and tumor metabolism: implications for cancer therapy.. Carcinogenesis 46(2) PMID: 40538377
- 8. Akkerman JW et al.. 1975. Human platelet 6-phosphofructokinase. Relation between inhibition by Mg-ATP2-and cooperativity towards fructose 6-phosphate and investigations on the formation of a ternary complex.. Biochim Biophys Acta 397(2):395-404 PMID: 125610
